On March 19, the FDA approved atezolizumab (Tecentriq®
, Genentech) in combination with carboplatin and etoposide (chemotherapy) for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Read the Roche press release here
Read the FDA press release here
Download the Tecentriq ES-SCLC Day 1 Letter here